US 12,344,584 B2
KCNQ potentiators
Helen Jane Szekeres, Bisley (GB); Maria Ann Whatton, Basingstoke (GB); and Andrew Caerwyn Williams, Woodley (GB)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Nov. 9, 2023, as Appl. No. 18/388,299.
Application 18/388,299 is a continuation of application No. 17/531,000, filed on Nov. 19, 2021, granted, now 11,840,516.
Application 17/531,000 is a continuation of application No. 16/781,148, filed on Feb. 4, 2020, granted, now 11,208,383, issued on Dec. 28, 2021.
Claims priority of provisional application 62/811,038, filed on Feb. 27, 2019.
Claims priority of provisional application 62/801,716, filed on Feb. 6, 2019.
Prior Publication US 2024/0076269 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 213/38 (2006.01); A61P 25/28 (2006.01); C07D 213/64 (2006.01)
CPC C07D 213/38 (2013.01) [A61P 25/28 (2018.01); C07D 213/64 (2013.01)] 5 Claims
 
1. A compound of the Formula:

OG Complex Work Unit Chemistry
wherein the compound comprises a single enantiomer that has the (+) optical rotation when measured at 20° C. and 589 nm at a concentration of 0.20 g/100 mL in methanol.